Reason why to buy and hold BPAX through Feb. 14th BPAX is partnered with TEVA TEVA knows drugs and how to get them approved.
BPAX Bio-T Gel up for FDA approval on Feb. 14th 2012! BPAX is extremely oversold currently trades between .65-.70cents price per share range. Potential to make huge gains on BPAX stock in only 2 short weeks. The price should start to uptrend as we get closer to Feb. 14th. Now is the time to buy. Don't miss the boat on this trying to get a cheaper price that will never come.
Biosante Pharmaceuticals Inc.
BPAX
Bio-T-Gel (NDA)
FDA decision on Bio-T-Gel for treatment of male hypogonadism or low testosterone levels
BPAX 14th Annual BIO CEO & Investor Conference, Feb-14-2012 10:30 AM IMO they would not be presenting unless they had something new to report - this is a very good sign.
BPAX Conference Schedule
BioSante Pharmaceuticals, Inc. Presents at Biotechnology Industry Organization's 14th Annual BIO CEO & Investor Conference, Feb-14-2012 10:30 AM
BioSante Pharmaceuticals, Inc. Presents at Citi Global Healthcare Conference 2012, Feb-27-2012 03:30 PM
BioSante Pharmaceuticals, Inc. Presents at 24th Annual OC Growth Stock Conference, Mar-11-2012
BioSante Pharmaceuticals, Inc. expected to report Fiscal Year 2011 results on March 15, 2012. This event was calculated by Capital IQ (Created on July 28, 2011).
Inventors: Stephen Simes (Long Grove, IL, US) Michael Snabes (Winnetka, IL, US) Joanne Zborowski (Lake Zurich, IL, US) Assignees: BIOSANTE PHARMACEUTICALS, INC. IPC8 Class: AA61K3156FI USPC Class: 514178 Class name: Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system Publication date: 01/26/2012 Patent application number: 20120022033
News 
Market Data 
Discover 
